 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma
Trial completion, Trial completion date, Trial primary completion date: SEAL: Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (clinicaltrials.gov) - Dec 29, 2021
P1, N=55, Completed, Sponsor: Vallon Pharmaceuticals, Inc.
Recruiting --> Completed | Trial completion date: Mar 2022 --> Dec 2021 | Trial primary completion date: Mar 2022 --> Dec 2021
- || abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma
Trial completion date, Trial primary completion date: SEAL: Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (clinicaltrials.gov) - Oct 26, 2021
P1, N=64, Recruiting, Sponsor: Vallon Pharmaceuticals, Inc.
Recruiting --> Completed | Trial completion date: Mar 2022 --> Dec 2021 | Trial primary completion date: Mar 2022 --> Dec 2021 Trial completion date: Sep 2021 --> Mar 2022 | Trial primary completion date: Sep 2021 --> Mar 2022
- abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma
[VIRTUAL] Vallon Pharmaceuticals () - Apr 3, 2021 - Abstract #BIO2021BIO_123;
The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection.
- || abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma
Trial completion date, Trial primary completion date: SEAL: Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (clinicaltrials.gov) - Feb 25, 2021
P1, N=64, Recruiting, Sponsor: Vallon Pharmaceuticals, Inc.
ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Jun 2021 --> Sep 2021
- ||| abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma
New P1 trial: SEAL: Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) (clinicaltrials.gov) - Nov 30, 2020
P1, N=64, Recruiting, Sponsor: Vallon Pharmaceuticals, Inc.
- abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma, dextroamphetamine immediate release / Generic mfg.
[VIRTUAL] Abuse-Deterrent Properties of a Novel Formulation of Immediate-Release Dextroamphetamine Compared to Reference Dextroamphetamine Immediate-Release () - Aug 29, 2020 - Abstract #AACAP2020AACAP_701;
- | abuse-deterrent amphetamine immediate-release (ADAIR) / Vallon Pharma
New P1 trial: Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR) (clinicaltrials.gov) - Jan 18, 2020
P1, N=16, Completed, Sponsor: Vallon Pharmaceuticals, Inc.